Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Stock Chart & Stats
$1.05
-$0.10(-5.71%)
At close: 4:00 PM EST
$1.05
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.66 - $1.94
Previous CloseN/A
Volume630.90K
Average Volume (3M)1.38M
Market Cap
$124.58M
Enterprise Value$13.76M
Total Cash (Recent Filing)$215.42M
Total Debt (Recent Filing)$79.25M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 02, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding115,352,290
10 Day Avg. Volume1,475,818
30 Day Avg. Volume1,375,366
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.59
Price to Sales (P/S)13.76
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue1.93
Enterprise Value/Gross Profit1.93
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$4.64Price Target Upside341.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$5.14M
Bulls Say, Bears Say
Bulls Say
Clinical Profile And Dosing StrategyFT819 demonstrated rapid, durable symptom improvements with an outpatient-compatible, repeat-dosing profile that could support low-toxicity immune resets for autoimmune patients.
Clinical Trial ExpansionFT825 and FT836 are enrolling solid tumor patients, including cohorts with confirmed HER2, broadening the oncology program and increasing potential clinical readouts.
Regulatory ApprovalsMHRA and EMA approvals to initiate FT819 autoimmune trials enable UK and EU clinical development and broaden the pool of eligible patients.
Bears Say
Competitive Efficacy RiskFailure of FT819 to show a clear efficacy advantage versus other allogeneic or autologous CAR-T approaches could limit adoption and pressure valuation.
Durability ConcernsMixed durability signals, such as rapid B-cell recovery in some regimens and at least one patient relapse about one year after dosing, create uncertainty around sustained benefit in lupus.
Safety, Immunogenicity And Execution RisksPotential unexpected safety or immunogenicity issues, plus partnership execution or regulatory setbacks, could delay trials or restrict future approval prospects.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.66 and its highest was $1.94 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $124.58M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Mar 02, 2026 which is in 44 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.292 by $0.022.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.28.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 115,352,290 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.292. Following the earnings report the stock price went down -4.615%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.64 (341.90% Upside)
$4.64 (341.90% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.45%
12-Months-Change
Fundamentals
Return on Equity
-52.35%
Trailing 12-Months
Asset Growth
-30.57%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$4.64
▲(341.90% Upside)
Technical Analysis
Ownership Overview
13.00% Insiders
13.26% Mutual Funds
0.14% Other Institutional Investors
64.46% Public Companies and
Individual Investors